ENTRADA THERAPEUTICS INC. news, videos and press releases
For more news please use our advanced search feature.
ENTRADA THERAPEUTICS INC. - More news...
ENTRADA THERAPEUTICS INC. - More news...
- Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping
- Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
- Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44
- Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy
- Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
- Entrada Therapeutics Reports Third Quarter 2024 Financial Results
- Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society
- Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development
- Entrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant Program
- Entrada Therapeutics Reports Second Quarter 2024 Financial Results
- Entrada Therapeutics Announces $100 Million Registered Direct Offering
- Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular Dystrophy
- Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference
- Entrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
- Entrada Therapeutics Reports First Quarter 2024 Financial Results
- Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
- Entrada Therapeutics to Present at Upcoming Investor Conferences
- Entrada Therapeutics Promotes Nathan J. Dowden to President
- Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy
- Entrada Therapeutics Reports Third Quarter 2023 Financial Results
- Entrada Therapeutics to Present at Upcoming Investor Conferences
- Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy
- Entrada Therapeutics Awards Funding to Non-Profit Organizations Advancing Diversity, Equity, Inclusion and Accessibility within the Duchenne Muscular Dystrophy Community
- Entrada Therapeutics to Present at Upcoming Investor Conferences
- Entrada Therapeutics Appoints Gina Chapman to its Board of Directors
- Entrada Therapeutics Reports Second Quarter 2023 Financial Results
- Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy
- Entrada Therapeutics to Present at Goldman Sachs 44th Annual Global Healthcare Conference
- Entrada Therapeutics Reports First Quarter 2023 Financial Results
- Entrada Therapeutics Appoints Dr. Bernhardt Zeiher to its Board of Directors
